We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+21.69%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.03B
AUM Growth
+$274M
Cap. Flow
+$156M
Cap. Flow %
15.15%
Top 10 Hldgs %
40.17%
Holding
97
New
37
Increased
20
Reduced
20
Closed
12

Top Buys

Rank Stock Value
1
HRTX icon
Heron Therapeutics
HRTX
+$29.8M
2
TVTX icon
Travere Therapeutics
TVTX
+$24.7M
3
CTRX
CATAMARAN CORP COM STK (CDA)
CTRX
+$22.5M
4
AEGR
Aegerion Pharmaceuticals
AEGR
+$20.5M
5
EBS icon
Emergent Biosolutions
EBS
+$18.5M

Top Sells

Rank Stock Value
1
LCI
Lannett Company, Inc.
LCI
+$25.5M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$25.4M
3
ASRT
Assertio
ASRT
+$19.7M
4
NVDQ
Novadaq Technologies Inc.
NVDQ
+$14.7M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$14.7M

Sector Composition

Rank Sector Weight
1 Healthcare 79.95%
2 Technology 0.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHIO icon
51
Phio Pharmaceuticals
PHIO
$12M
$4.81M 0.47%
+2
New +$6.35M
TRVN
52
DELISTED
Trevena, Inc.
TRVN
$4.72M 0.46%
+960
New +$4.71M
PLXP
53
DELISTED
PLx Pharma Inc. Common Stock
PLXP
$4.63M 0.45%
+57,475
New +$5.27M
SCTL
54
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$4.61M 0.45%
+702,450
New +$5.1M
QLTI
55
DELISTED
QLT Inc
QLTI
$4.36M 0.42%
784,893
– –
THOR
56
DELISTED
THORATEC CORPORATION
THOR
$4.36M 0.42%
+121,867
New +$4.37M
FLXN
57
DELISTED
Flexion Therapeutics, Inc.
FLXN
$4.33M 0.42%
+263,204
New +$4.55M
FLNA
58
Filana Therapeutics
FLNA
$51.2M
$4.29M 0.42%
111,429
-64,285
-37% -$2.27M
INO icon
59
Inovio Pharmaceuticals
INO
$92.1M
$4.16M 0.4%
+26,042
New +$3.74M
ITCI
60
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$4.08M 0.4%
+224,234
New +$4.05M
VXRT
61
DELISTED
Vaxart
VXRT
$3.89M 0.38%
+57,882
New +$3.58M
RDHL
62
Redhill Biopharma
RDHL
$4.29M
$3.71M 0.36%
+263
New +$3.52M
SRPT icon
63
Sarepta Therapeutics
SRPT
$1.82B
$3.64M 0.35%
151,655
-575,000
-79% -$14.7M
ALBO
64
DELISTED
Albireo Pharma Inc
ALBO
$3.63M 0.35%
44,334
+11,001
+33% +$1M
OMER icon
65
Omeros
OMER
$701M
$3.62M 0.35%
+300,000
New +$3.69M
MRTX
66
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$3.52M 0.34%
184,756
-29,530
-14% -$614K
AGEN
67
Agenus
AGEN
$209M
$3.34M 0.32%
+53,752
New +$3.74M
ACHN
68
DELISTED
Achillion Pharmaceuticals
ACHN
$3.29M 0.32%
1,000,000
– –
LJPC
69
DELISTED
La Jolla Pharmaceutical Company
LJPC
$3.24M 0.31%
+300,000
New +$2.94M
CASM
70
DELISTED
CAS Medical Systems, Inc.
CASM
$3.09M 0.3%
1,424,796
+75,000
+6% +$159K
AKTX
71
Akari Therapeutics
AKTX
$19.3M
$3.06M 0.3%
+59
New +$3.34M
OFIX icon
72
Orthofix Medical
OFIX
$468M
$3.02M 0.29%
+100,000
New +$2.31M
SSKN
73
DELISTED
Strata Skin Sciences
SSKN
$2.97M 0.29%
+8
New +$2.81K
TXMD icon
74
TherapeuticsMD
TXMD
$23.8M
$2.9M 0.28%
9,177
-33,386
-78% -$10.6M
CNCE
75
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$2.69M 0.26%
+200,000
New +$2.82M
1 2
3
4

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q1 2014 Portfolio in Review

As of Q1 2014, Broadfin Capital held 97 positions worth $1.03B, up 36% from $758M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Broadfin Capital deployed $156M of net new capital in Q1 2014, opening 37 new positions and adding to 20 existing holdings. Its largest new stake was Heron Therapeutics: 2,233,173 shares worth $31.1M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 76% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Lannett Company, Inc., an estimated $25.5M trimmed.

  • Broadfin Capital's largest Q1 2014 buy was Heron Therapeutics: 2,233,173 shares worth $31.1M.
  • Broadfin Capital added most to Emergent Biosolutions in Q1 2014, an estimated $18.5M increase.
  • Broadfin Capital's biggest Q1 2014 reduction was Lannett Company, Inc., cutting an estimated $25.5M.
  • Broadfin Capital fully exited NPS PHARMACEUTICALS INC in Q1 2014, selling an estimated $12.1M.
  • Broadfin Capital's ten largest holdings make up 40% of its $1.03B portfolio in Q1 2014.
  • Broadfin Capital opened 37 new positions and closed 12 in Q1 2014.
  • Broadfin Capital's portfolio value rose 36% quarter-over-quarter to $1.03B.

Based on Broadfin Capital's 13F filing for Q1 2014, filed 15 May 2014.